1. < Home

Allergy & Immunology

Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma

Pavord ID, Deniz Y, Corren J, Casale TB, FitzGerald JM, Izuhara K, Daizadeh N, Ortiz B, Johnson RR, Harel S, Djandji M, Goga L, Crikelair[...]

By sjmartinez • April 11, 2023
Electronic Patient Portal Activation and Outcomes Among Pediatric Patients with Asthma

Kafashzadeh D, Hall K, Pirani C, Szilagyi PG, Chen L, Ross MK. Electronic Patient Portal Activation and Outcomes Among Pediatric Patients with Asthma. J Allergy[...]

By sjmartinez • March 23, 2023
Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma

Corren J, Wechsler ME, Chupp G, Roseti SL, Hellqvist Å, Martin N, Llanos JP, Ambrose CS, Colice G. Efficacy and safety of tezepelumab in patients[...]

By sjmartinez • March 14, 2023
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Craig TJ, Reshef A, Li HH, Jacobs JS, Bernstein JA, Farkas H, Yang WH, Stroes ESG, Ohsawa I, Tachdjian R, Manning ME, Lumry WR, Saguer[...]

By sjmartinez • March 4, 2023